Immuno-Oncology

Webinar Series

 2020

LUMICKS invites you to attend our Immuno-Oncology (IO) webinars.

 

The series of webinars, delivered by our application scientists or by invited speakers, cover topics across the field of immunotherapy, such as CAR-T and TCR T-cell therapy .

If you are curious about cell avidity or are looking for a new workflow that can help you predict the immunotherapeutic potential of your cells, click on the link below to register to our webinars or download recordings!

Upcoming Webinars

Deep-dive into the applications with LUMICKS’ scientists and world-leading experts.

Join our upcoming webinars presented by expert speakers and world-renowned researchers, covering the latest breakthroughs and developments in immuno-oncology.

Prof. Carlos Fernández
Universitat de Barcelona

Dual-targeted CAR T cell therapy targeting BCMA and GPRCD5 to prevent relapse in myeloma

Monday, 19 October 2020, 8:00 AM (PDT)

Learn from Prof. Fernández de Larrea and his group how expressing two CARs on a single cell enhances the strength of CAR T-cell/target cell interactions and can prevent BCMA escape-driven relapse in multiple myeloma and discover how cell avidity measurements can indicate which CAR-T cell panels are showing higher interaction force with target cells.

On-demand Webinars

Dr. Rogier Reijmers
LUMICKS

Cellular avidity – a missing link for efficacious immunotherapy

During this talk we presented proof-of-concept experiments across the topics of CAR-T cells, TCR T cells, NK cells and bispecific antibody-engaged T cells, showing correlation between avidity and T cell functionality using the z-Movi® Cell Avidity Analyzer.

Dr. Rogier Reijmers
LUMICKS

Fast and accurate prediction of optimal TCR function using z-Movi® Cell Avidity Analyzer

How does the z-Movi® measure cell avidity? Why does avidity matter in TCR-dependent T-cell cytotoxicity? How does it compare with functional assays?

Dr. Rogier Reijmers
LUMICKS

Rapid identification of Goldilocks CAR T cells using z-Movi® Cell Avidity Analyzer

How can measuring cellular avidity using z-Movi® help quickly identify optimal functioning CARs?

Dr. John Maher
Leucid Bio

CAR T-Cell Immunotherapy of Solid Tumors – Learning from the Clinic and Lab in Parallel

Learn about Leucid Bio’s efforts in developing a next generation CAR platform, known as parallel (p)CAR. How does Dr. John Maher use the z-Movi to address the importance of relative binding affinity in the design of optimized pCAR?

External Application Webinars

Watch seminars from world-leading experts.

Don’t miss researchers from external institution (why would I be interested for talks from external institutions?) world-renowned researchers talk about their experience with cell avidity measurements for T cell functionality prediction.

Cell avidity – the best predictor for clinical efficacy of T-cell therapy?

Affinity between immune-cell receptors and their antigens has been shown to be a poor predictor of T-cell functionality. The webinar will discuss the benefits of avidity, a new parameter to assess functionality of immune cells, with the potential to improve workflows for the development of immunotherapy against cancer.

To this end, we will present proof-of-concept experiments across the topics of CAR-T cells, TCR T cells, NK cells and bispecific antibody-engaged T cells, showing correlation between avidity and T cell functionality.

We will introduce the z-Movi® Cell Avidity Analyzer, a novel and unique instrument that makes use of ultrasound to directly measure the avidity between immune cells and their target cancer cells.

Date: Wednesday, 2 September 2020

Speaker: Dr. Rogier Reijmers, Principal Scientist Immuno-Oncology, LUMICKS

Event: PEGS Boston Virtual Summit

Date: Wednesday, 23 September 2020, time?

Speaker: Dr. John Maher, Clinical Immunologist, Scientific Founder and CEO of Leucid Bio

Platform: Labroots (this info is relevant only to our competitors)

CAR T-Cell Immunotherapy of Solid Tumors – Learning from the Clinic and Lab in Parallel

In this webinar, Dr. John Maher will update on the clinical trial of CAR-T immunotherapy in patients with head and neck cancer using a panErbB-targeted second generation CAR, known as T4 immunotherapy.

He will also describe his efforts to develop a next generation CAR platform known as a parallel (p)CAR in which optimized co-stimulation is delivered by a paired second generation CAR and chimeric co-stimulatory receptor.

He will explain how they selected targeting moieties for this approach using the z-Movi® technology in order to address the importance of relative binding affinity in the design of optimized pCAR. He will also provide a range of exemplifications of this technology involving distinct targets, binding modules, co-stimulatory modules, and tumor models.

his image should be enough, we can skip the data

Feedback for PEGS:

Perhaps for the creative you can put a PEGS banner instead of the video to make it even more clear that it is happening during the meeting.

Another suggestion would be to have both labroots and PEGS webinars together under upcoming webinars (with world-renowed and expert speakers) to consolidate a bit the information and make it easier to get the overview. I am a bit overwhelmed by this page as there is a lot of information altogether. Alternartively you can follow a format like in the DSM webinars where the info is even more structured and consolidated with the webinars one next to each other. All titles are interesting and unique so they should  catch attention by themselves or by the speaker alone.

Fast and accurate prediction of optimal TCR function using z-Movi® Cell Avidity Analyzer

In this webinar, we show the ease of use of the z-Movi and how to quickly acquire cellular avidity data, a valuable new parameter to assess T-cell functionality, using T cells expressing transgenic TCRs for immunotherapy development.

Learning objectives:
• How z-Movi measures cellular avidity.
• Why avidity matters in TCR-dependent T-cell cytotoxicity.
• How cell avidity measurements compare with in vitro functional assays.

Speaker: Dr. Rogier Reijmers, Principal Scientist Immuno-Oncology, LUMICKS

Fast and accurate prediction of optimal TCR function using z-Movi® Cell Avidity Analyzer

In this webinar, we show the ease of use of the z-Movi and how to quickly acquire cellular avidity data, a valuable new parameter to assess T cell functionality, using T cells expressing transgenic TCRs for immunotherapy development.

Learning objectives:
• How z-Movi measures cellular avidity.
• Why avidity matters in TCR-dependent T-cell cytotoxicity.
• How cell avidity measurements compare with in vitro functional assays.

Speaker: Dr. Rogier Reijmers, Principal Scientist Immuno-Oncology, LUMICKS

Rapid identification of Goldilocks CAR T cells using z-Movi® Cell Avidity Analyzer

In this webinar we demonstrate that measuring cellular avidity, i.e. overall binding strength between effector and target cell, using z-Movi® Cell Avidity Analyzer can help quickly identify optimal functioning CARs.

Learning objectives:
• How z-Movi measures cellular avidity.
• Why avidity matters in CAR-dependent T-cell cytotoxicity.
• How cell avidity measurements compare with functional assays.

Speaker: Dr. Rogier Reijmers, Principal Scientist Immuno-Oncology, LUMICKS

Rapid identification of Goldilocks CAR T cells using z-Movi® Cell Avidity Analyzer

In this webinar we demonstrate that measuring cellular avidity, i.e. overall binding strength between effector and target cell, using z-Movi® Cell Avidity Analyzer can help quickly identify optimal functioning CARs.

Learning objectives:
• How z-Movi measures cellular avidity.
• Why avidity matters in CAR-dependent T-cell cytotoxicity.
• How cell avidity measurements compare with functional assays.

Speaker: Dr. Rogier Reijmers, Principal Scientist Immuno-Oncology, LUMICKS

Watch Past Webinars

Missed a webinar? Watch it on-demand below. A video recording and a slide deck are now available on our website.

Fill in the form below to watch previously-held webinars. If you miss something don’t hesitate to let us know!

Join our mailing list.

Get exclusive news on the latest products, single-molecule events and breakthrough science.

By agreeing to receive marketing communications, you subscribe to our newsletter. You can change your mind at any time by clicking the unsubscribe link in any marketing email you receive from us. By submitting the form you agree to LUMICKS' privacy policy.

Take your research to the next level.

Get exclusive news on the latest products, single-molecule events and breakthrough science.

Newsletter pop up
By clicking the subscribe button you agree to LUMICKS’ privacy policy.